

DMP1 $\beta$ IHC vs clinical stages										
Stage	I	IIA	IIB	IIA or B	IIIA	IIIB	IIIC	IV	unknown	total
IHC 0-3 (%)	3 (10.7)	13 (46.4)	3 (10.7)	1 (3.6)	6 (21.4)	1 (3.6)	0 (0)	0 (0)	1 (3.6)	28
IHC 4-6 (%)	14 (40.0)	4 (11.4)	4 (11.4)	0 (0)	6 (17.1)	3 (8.6)	2 (5.7)	1 (2.9)	1 (2.9)	35
	$p = 0.0218, \chi^2 = 5.26$ DMP1 $\beta$ IHC 4-6 intensity associated with stage I									
DMP1 $\beta/\alpha$ ratio vs clinical stages										
Stage	I	IIA	IIB	IIA or B	IIIA	IIIB	IIIC	IV	unknown	total
DMP1 $\beta/\alpha$ high (%)	7 (50)	3 (21.4)	3 (21.4)	0 (0)	0 (0)	0 (0)	1 (7.1)	0 (0)	0 (0)	14
DMP1 $\beta/\alpha$ low (%)	8 (25)	12 (37.5)	3 (9.4)	1 (3.1)	7 (21.9)	0 (0)	0 (0)	1 (3.1)	0 (0)	32
	$p = 0.1189, \chi^2 = 2.432$									
DMP1 $\beta$ IHC vs subclass										
Classification	luminal A	liminal B	HER2	triple neg	normal	unclassified	total			
IHC 0-3 (%)	9 (32.1)	6 (21.4)	5 (17.9)	4 (14.3)	1 (3.6)	3 (10.7)	28			
IHC 4-6 (%)	12 (34.3)	9 (25.7)	7 (20.0)	4 (11.4)	0 (0)	3 (8.6)	35			
	$p = 0.7642, \chi^2 = 0.09$									
DMP1 $\beta/\alpha$ ratio vs subclass										
Classification	luminal A	liminal B	HER2	triple neg	normal	unclassified	total			
DMP1 $\beta/\alpha$ high (%)	7 (50)	3 (21.4)	1 (7.1)	2 (14.3)	0 (0)	1 (7.1)	14			
DMP1 $\beta/\alpha$ low (%)	7 (21.9)	10 (31.3)	8 (25)	5 (15.6)	2 (6.3)	0 (0)	32			
	$p = 0.1189, \chi^2 = 2.432$									

### Supplementary Table 1. Correlation of DMP1 $\beta$ expression with current histological and molecular classifications of human breast cancer.

Currently used prognostic indicators, clinical stage and sub-classification, for breast cancer were correlated to DMP1 $\beta$  protein (IHC) expression and aberrant *DMP1 $\beta/\alpha$*  splicing. High DMP1 $\beta$  protein staining in IHC was found associated with stage I of breast cancer ( $p = 0.0218, \chi^2 = 5.26$ ). Aberrant *DMP1 $\beta/\alpha$*  (high) ratios were found to trend with stage I, but the data were not statistically significant.